ConferenceLeukemia and LymphomaClinical February 16th 2025 Can a New Therapeutic Combo Address a Rare Form of RCC? Mary Caffrey Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven...
An abstract is unavailable.DiGiulioSarah